SK286967B6 - Spontánne dispergovateľná farmaceutická kompozícia N-benzoylstaurosporínu - Google Patents

Spontánne dispergovateľná farmaceutická kompozícia N-benzoylstaurosporínu Download PDF

Info

Publication number
SK286967B6
SK286967B6 SK1172-2001A SK11722001A SK286967B6 SK 286967 B6 SK286967 B6 SK 286967B6 SK 11722001 A SK11722001 A SK 11722001A SK 286967 B6 SK286967 B6 SK 286967B6
Authority
SK
Slovakia
Prior art keywords
surfactant
composition
benzoylstaurosporine
pharmaceutical composition
hydrophilic
Prior art date
Application number
SK1172-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK11722001A3 (sk
Inventor
Graham Paul Matthews
Barbara H�Berlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286967(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK11722001A3 publication Critical patent/SK11722001A3/sk
Publication of SK286967B6 publication Critical patent/SK286967B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1172-2001A 1999-02-16 2000-02-14 Spontánne dispergovateľná farmaceutická kompozícia N-benzoylstaurosporínu SK286967B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds
PCT/EP2000/001196 WO2000048571A1 (en) 1999-02-16 2000-02-14 Spontaneously dispersible n-benzoyl staurosporine compositions

Publications (2)

Publication Number Publication Date
SK11722001A3 SK11722001A3 (sk) 2001-12-03
SK286967B6 true SK286967B6 (sk) 2009-08-06

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1172-2001A SK286967B6 (sk) 1999-02-16 2000-02-14 Spontánne dispergovateľná farmaceutická kompozícia N-benzoylstaurosporínu

Country Status (34)

Country Link
US (3) US20020061873A1 (https=)
EP (1) EP1152750B1 (https=)
JP (2) JP5057610B2 (https=)
KR (2) KR100880859B1 (https=)
CN (1) CN100367930C (https=)
AR (2) AR022589A1 (https=)
AT (1) ATE430554T1 (https=)
AU (1) AU765776B2 (https=)
BR (1) BRPI0008228B8 (https=)
CA (1) CA2362277C (https=)
CL (1) CL2009001682A1 (https=)
CZ (1) CZ303979B6 (https=)
DE (1) DE60042151D1 (https=)
DK (1) DK1152750T3 (https=)
EC (1) ECSP083351A (https=)
ES (1) ES2326783T3 (https=)
GB (1) GB9903547D0 (https=)
HK (1) HK1045807B (https=)
HU (1) HUP0105364A3 (https=)
ID (1) ID30504A (https=)
IL (3) IL144512A0 (https=)
MY (1) MY128362A (https=)
NO (1) NO331232B1 (https=)
NZ (1) NZ513529A (https=)
PE (1) PE20001499A1 (https=)
PL (1) PL198330B1 (https=)
PT (1) PT1152750E (https=)
RU (1) RU2266121C2 (https=)
SI (1) SI1152750T1 (https=)
SK (1) SK286967B6 (https=)
TR (1) TR200102385T2 (https=)
TW (1) TWI240636B (https=)
WO (1) WO2000048571A1 (https=)
ZA (1) ZA200106677B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
PT1372611E (pt) * 2001-03-26 2006-08-31 Novartis Ag Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
CA2444867C (en) 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
DE60213842T2 (de) * 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1531793A1 (en) * 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
JP5546860B2 (ja) * 2006-08-16 2014-07-09 ノバルティス アーゲー 高結晶性治療化合物の固体分散体を製造するための方法
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
US20120322776A1 (en) * 2009-12-22 2012-12-20 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
US9387446B2 (en) * 2011-09-22 2016-07-12 Ariel-University Research And Development Company Ltd. Emulsions and methods of making emulsions
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (https=) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
WO1998013032A1 (en) 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
SK285019B6 (sk) * 1997-01-30 2006-04-06 Novartis Ag Tvrdá želatínová tobolka
ATE265847T1 (de) 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
PL192080B1 (pl) 1997-07-29 2006-08-31 Upjohn Co Kompozycja farmaceutyczna zawierająca związek piranonowy
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
TWI240636B (en) 2005-10-01
ES2326783T3 (es) 2009-10-20
NO331232B1 (no) 2011-11-07
TR200102385T2 (tr) 2002-09-23
GB9903547D0 (en) 1999-04-07
PL198330B1 (pl) 2008-06-30
JP5057610B2 (ja) 2012-10-24
US20080070897A1 (en) 2008-03-20
ATE430554T1 (de) 2009-05-15
ZA200106677B (en) 2003-01-14
IL144512A (en) 2011-03-31
ID30504A (id) 2001-12-13
WO2000048571A1 (en) 2000-08-24
SK11722001A3 (sk) 2001-12-03
DE60042151D1 (de) 2009-06-18
CZ20012931A3 (cs) 2001-11-14
KR100880859B1 (ko) 2009-01-30
ECSP083351A (es) 2008-08-29
HUP0105364A3 (en) 2003-02-28
US20020061873A1 (en) 2002-05-23
BRPI0008228B8 (pt) 2021-05-25
JP2012111763A (ja) 2012-06-14
BR0008228A (pt) 2001-10-30
US8722664B2 (en) 2014-05-13
MY128362A (en) 2007-01-31
IL144512A0 (en) 2002-05-23
NO20013964L (no) 2001-10-15
KR20080064914A (ko) 2008-07-09
AU3154200A (en) 2000-09-04
AU765776B2 (en) 2003-10-02
US8575147B2 (en) 2013-11-05
CN100367930C (zh) 2008-02-13
CL2009001682A1 (es) 2010-07-23
CZ303979B6 (cs) 2013-07-31
AR022589A1 (es) 2002-09-04
PL350556A1 (en) 2002-12-16
NO20013964D0 (no) 2001-08-15
DK1152750T3 (da) 2009-08-24
EP1152750A1 (en) 2001-11-14
CA2362277C (en) 2010-03-30
CA2362277A1 (en) 2000-08-24
HK1045807B (zh) 2008-12-05
PT1152750E (pt) 2009-08-07
SI1152750T1 (sl) 2009-10-31
EP1152750B1 (en) 2009-05-06
RU2266121C2 (ru) 2005-12-20
HK1045807A1 (zh) 2002-12-13
CN1339963A (zh) 2002-03-13
JP2002537242A (ja) 2002-11-05
PE20001499A1 (es) 2001-01-12
IL192666A0 (en) 2009-02-11
KR20010093281A (ko) 2001-10-27
NZ513529A (en) 2003-10-31
BRPI0008228B1 (pt) 2016-08-23
HUP0105364A2 (hu) 2002-05-29
AR082579A2 (es) 2012-12-19
US20140056974A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
US8722664B2 (en) Spontaneously dispersible N-benzoyl staurosporine compositions
ES2239605T3 (es) Composiciones de ciclosporina substancialmente libres de aceites.
RU2639482C2 (ru) Фармацевтические композиции
AU755134B2 (en) Microemulsion preconcentrates containing a piperidine substance P antagonist
RU2235554C2 (ru) Предварительно приготовленные эмульсионные концентраты, содержащие циклоспорин или макролид
MXPA01008293A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
HK1035137B (en) Microemulsion preconcentrates containing a piperidine substance p antagonist
ZA200006597B (en) Microemulsion preconcentrates containing a piperidine substance p antagonist.

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20200214